BioTuesdays

Tag - SVB Leerink

Zymeworks Logo

SVB Leerink ups Zymeworks to OP from MP

SVB Leerink upgraded Zymeworks (NYSE:ZYME) to “outperform” from “market perform,” citing a sell-off in the stock that “makes us more constructive, despite some uncertainties.” The stock closed at $16.12 on Dec. 9.  ...

Aura Biosciences

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

Airsculpt Technologies

SVB Leerink starts Airsculpt at OP; PT $26

SVB Leerink launched coverage of Airsculpt Technologies (NASDAQ:AIRS) with an “outperform” rating and price target of $26. The stock closed at $13.61 on Nov. 22. Airsculpt has created an innovative luxury consumer brand...

Minerva Surgical

Analysts start Minerva Surgical at OW, OP; PT $17

Piper Sandler and SVB Leerink launched coverage of Minerva Surgical (NASDAQ:UTRS) with “overweight” and “outperform” ratings, respectively, and price targets of $17. The stock closed at $9.62 on Nov. 15. Minerva, which...

Theseus Pharmaceuticals

SVB Leerink starts Theseus Pharma at OP; PT $28

SVB Leerink launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with an “outperform” rating and $28 price target. The stock closed at $17.12 on Oct. 29. Theseus is a biopharmaceutical company focused on “pan...

Atea Pharmaceuticals

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

Dice-Therapeutics

SVB Leerink starts DICE Therapeutics at OP; PT $46

SVB Leerink launched coverage of Dice Therapeutics (NASDAQ:DICE) with an “outperform” rating and $46 price target. The stock closed at $26.49 on Oct. 8. DICE is a biopharmaceutical company leveraging its proprietary...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.